24/7 Wall Street
18 May 2026, 11:35 UTC · 18w ago
Verdict
Headline leans bullish. We score TEM +0.60 across five claims.
Score confirms the headline.
Leans bullish
From its wording — no explicit rating
+0.60strongly bullish
What the story claims
5 claims · scored −1 bearish … +1 bullish
Hims & Hers Health faces unresolved FDA and securities lawsuits regarding compounded GLP-1s and a Q1 2026 EPS miss of nearly 397%.
More negative than 99% of claims this week
Tempus AI reported 83% YoY revenue growth in Q4 2025 and provided 2026 revenue guidance of $1.59 billion.
Continue reading
5 related stories
More positive than 75% of ticker scores this week
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
More positive than 93% of claims this week
Doximity's FY2027 revenue guidance ($664M-$676M) implies a meaningful growth deceleration compared to FY2026 revenue of $644.86M.
So whatProjected slowdown in revenue growth typically leads to multiple compression for growth-oriented tech stocks.
More negative than 86% of claims this week
Nurix Therapeutics is advancing its lead asset bexobrutideg into a Phase 3 study starting mid-2026 with $540.73 million in cash runway.
So whatProgressing to Phase 3 with a strong cash position reduces immediate bankruptcy risk and increases the probability of a clinical catalyst.
More positive than 78% of claims this week
Schrodinger's operating cash flow swung from positive $144 million to negative $14.83 million year over year.
So whatA sharp reversal in cash flow indicates increasing burn and potential need for dilutive financing.
More negative than 78% of claims this week
Which stocks this story touches
More positive than 75% of ticker scores this week
Strong revenue growth and positive EBITDA flip, though offset by high debt and dilution risks.
More positive than 69% of ticker scores this week
Positive analyst ratings and promising clinical pipeline, despite a significant drop in Q1 revenue.
More positive than 65% of ticker scores this week
Strong cash flow and AI tool adoption, though facing potential growth deceleration in FY2027.
More positive than 60% of ticker scores this week
Mentioned in the context of a validating $2.3 billion acquisition of Ajax Therapeutics.
More positive than 60% of ticker scores this week
Validation from the Ajax acquisition and upcoming AI product launch, despite meaningful cash burn.
More positive than 54% of ticker scores this week
Mentioned as a deepening partner for Tempus AI and collaborator for Nurix Therapeutics.
More positive than 54% of ticker scores this week
Mentioned as a deepening partner for Tempus AI.
More positive than 54% of ticker scores this week
Mentioned as a branded GLP-1 partner for Hims & Hers.
More positive than 54% of ticker scores this week
Mentioned as a deepening partner for Tempus AI (Daiichi Sankyo).
More negative than 65% of ticker scores this week
Explicitly mentioned as being excluded from a top 10 stocks list by a prominent analyst.
More positive than 54% of ticker scores this week
Raised revenue guidance and international growth are countered by a massive EPS miss and ongoing lawsuits.
More positive than 48% of ticker scores this week
Mentioned as a collaborator for Nurix Therapeutics.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
More positive than 34% of relationship scores this week
[mutual] Tempus AI has deepening partnerships with Daiichi Sankyo for AI-driven drug discovery.
More positive than 34% of relationship scores this week
[mutual] Tempus AI has deepening partnerships with Gilead for AI-driven drug discovery.
More positive than 34% of relationship scores this week
[mutual] Tempus AI has deepening partnerships with Merck for AI-driven drug discovery.
More positive than 34% of relationship scores this week
[mutual] Nurix Therapeutics has active collaborations with Gilead including profit-share opt-ins.
More positive than 34% of relationship scores this week
[mutual] Nurix Therapeutics has active collaborations with Pfizer.
More positive than 34% of relationship scores this week
[mutual] Nurix Therapeutics has active collaborations with Sanofi.
More positive than 2% of relationship scores this week
[mutual] Eli Lilly's pending acquisition of Ajax Therapeutics validates the ecosystem where Schrodinger holds a stake.
+87.2%
Price agrees with the score
$82.24 vs $43.93 close before publication (May 15) · not market-adjusted
TEM chart →
